Sign up
Pharma Capital

NetScientific portfolio company Vortex presents study to combine technology with impedance spectroscopy

The healthcare IP commercialisation group said the study introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells
Cells and test tubes
The study will be presented at the NanoBiotech Montreux 2018 conference in Switzerland

NetScientific PLC (LON:NSCI) said its portfolio company, Vortex BioSciences, has presented a study demonstrating how its technology can combine with impedance spectroscopy to improve the analysis of circulating tumour cells (CTCs).

The healthcare IP commercialisation group said the study, presented at the NanoBiotech Montreux 2018 conference in Switzerland, introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells isolated from blood samples.

READ: NetScientific portfolio company Vortex enters manufacturing partnership with STRATEC

The researchers believed the results of the study provided feasibility for label-free, reliable, fully-integrated cell enumeration, whilst keeping the cells collected intact for downstream transcriptomic, genomic or proteomic analysis.

Impedance spectroscopy involves applying a wave frequency to a system or surface and measuring the changes and is often used on various types of biological tissue.

Francois Martelet, chief executive of NetScientific and chairman of Vortex, said Vortex’s technology was “ready to be adopted by large pharmaceutical players” following the creation of an automated and reliable process and the signing of a manufacturing agreement with German firm STRATEC for its VTX-1 liquid biopsy platform in November.

View full NSCI profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.